Clinical trials: Stage IV NSCLC
NSCLC Stage IV
AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
The goal of our project is building a predictive response algorithm for patients with metastatic lung cancer, exploiting an artificial intelligence platform.
- Trial name
- NCT06788366
- Testing
- Immunotherapy, Chemotherapy
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS San Raffaele
NSCLC Stage IIIB~IV
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
MS-20 was approved as the first oral cancer adjuvant new drug indicated for ameliorating fatigue and appetite loss associated with cancer chemotherapy via reshaping human gut ecosystem and restoring immunity.
- Trial name
- NCT04909034
- Testing
- MS-20
- Where
- 7 sites in Taiwan
- Volunteers
- 15 people
- Sponsor
- Microbio Co Ltd
NSCLC Stage IV
Cancer Patient Remote Monitoring for Timely Communication Study
The study is designed as a prospective, single-arm observational, mixed-method study. Patients with stage IV NSCLC or inoperable mesothelioma will be included and will be treated with immunotherapy according to current guidelines…
- Trial name
- CONNECT (NCT06623786)
- Volunteers
- 100 people
- Sponsor
- Asklepios proresearch
Stage IV NSCLC
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
Veterans with advanced lung cancer may benefit from recent advances in technologies that is designed to change the activities of their own white blood cells and help kill tumors.
- Trial name
- HAITEN-ICI (NCT06064279)
- Testing
- Poly ICLC, IVIG
- Where
- United States
- Sponsor
- VA Office of Research and Development
Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if Stereotactic Body Radiotherapy (SBRT) can treat the oligo-progressive metastatic non-small cell lung cancer (NSCLC) after first-line chemotherapy.
- Conditions
- Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease
- Trial name
- OPPRESS (NCT06523673)
- Testing
- Stereotactic Body Radiotherapy, second-line systemic therapy
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
NSCLC Stage IV, EGFR Activating Mutation
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
This study is an open-label, single-arm phase 2 trial to evaluate the efficacy and safety of stereotactic radiotherapy (SRT) for patients with oligo-residual NSCLC after 3rd generation EGFR-TKIs.
- Trial name
- NCT04764214
- Testing
- 3rd generation EGFR-TKI, Consolidative SRT
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fudan University
NSCLC Stage IV, Sex Disorder
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Although many phase III clinical trials evaluate the quality of life as a secondary endpoint, male sexuality remains a neglected topic in oncology research.
- Conditions
- NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction
- Trial name
- EROS (NCT06532149)
- Testing
- Alectinib, Brigatinib, Lorlatinib 100 mg
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ALK Gene Mutation, NSCLC Stage IV
Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
The scope of GALILEO project (Genomic ALteratIons and cLonal EvOlution in ALK+ NSCLC) is to explore the feasibility of genomic longitudinal evaluation for ALK+ NSCLC patients in Italian routine practice and provide a detailed…
- Conditions
- ALK Gene Mutation, NSCLC Stage IV, ALK Sensitizing Mutation
- Trial name
- GALILEO (NCT06234579)
- Testing
- Biopsy (tissue or liquid)
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NSCLC Stage IV, EGFR Gene Mutation
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
STEREO is single-arm phase II study, which aims to evaluate the safety and efficacy of osimertinib combined with early locally ablative radiotherapy of all cancer sites in patients with synchronous oligo-metastatic (primary…
- Trial name
- STEREO (NCT04908956)
- Testing
- Osimertinib, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 18 sites in Italy, Netherlands and 6 more
- Volunteers
- 6 people
- Sponsor
- ETOP IBCSG Partners Foundation
NSCLC Stage IV, NSCLC Stage IIIB
Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)
This phase Ib/II trial studies how well cadonilimab combined with anlotinib and docetaxel work in treating patients with non-small cell lung cancer that is stage IV or has come back.
- Conditions
- NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC
- Trial name
- AK104IIT018 (NCT05816499)
- Testing
- Cadonilimab, Anlotinib, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
NSCLC Stage IV
Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
This study is a multicenter, randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy (LDRT and SBRT) in the first-line treatment of immunotherapy…
- Trial name
- NCT06313541
- Testing
- SBRT or LDRT, PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Fudan University
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD
Advanced Lung Carcinoma, First Line Treatment
Exercise in Patients With Advanced Non-small Cell Lung Cancer
Lung cancer is one of the most common types of cancer in Germany, with 56,839 new cases and 45,072 deaths annually. Approximately 70% of patients with non-small cell lung cancer (NSCLC) are diagnosed at an advanced stage and…
- Conditions
- Advanced Lung Carcinoma, First Line Treatment, Second Line Treatment, NSCLC Stage IV
- Trial name
- BREATH (NCT06374160)
- Testing
- Exercise intervention
- Where
- Germany
- Volunteers
- 104 people
- Sponsor
- University Hospital, Essen
NSCLC Stage IV
Alectinib-induced Endocrine Toxicity
The experimental Cohort A (male ALK+ ANSCLC patients receiving alectinib), the control Cohort B (female ALK+ ANSCLC patients receiving alectinib) and control Cohort C (male NON-ALK ANSCLC patients) were prospectively evaluated…
- Trial name
- TOSS-ALK (NCT06339554)
- Testing
- Alectinib 150 MG [Alecensa]
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Cancer, NSCLC
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IV
- Trial name
- TUMORIN (NCT05332925)
- Testing
- Standard of care immune checkpoint inhbitors
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jun Zhang, MD, PhD
NSCLC Stage IV, NSCLC, Stage IIIC
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
This Observational study will explore the utility of the Biodesix, Inc. "PIR" (primary immune response) test to predict outcomes in treatment-naïve advanced stage NSCLC with PD-L1 tumor proportion score (TPS) > 50% and ECOG…
- Trial name
- BEACON-LUNG (NCT04676386)
- Testing
- Primary Immune Response (PIR) test by Biodesix, Inc.
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Addario Lung Cancer Medical Institute
NSCLC Stage IV
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
This is a Phase 1, open-label, multicenter, dose escalation study of HY1272 (administered via IV) evaluating both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in patients diagnosed with locally advanced or…
- Trial name
- NCT06218940
- Testing
- HY1272
- Volunteers
- 40 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
NSCLC, NSCLC Stage IV
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
This is a prospective, non-randomized, single arm, single institution phase II trial to evaluate the safety and effectiveness of stereotactic ablative radiotherapy (SABR) in oncogene addicted and non-oncogene addicted synchronous…
- Conditions
- NSCLC, NSCLC Stage IV, Oligometastatic Disease, Non Small Cell Lung Cancer
- Trial name
- STARTNEWERA-OM (NCT06207292)
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Radiotherapy Oncology Centre "Santa Maria" Hospital
Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC)
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does…
- Conditions
- Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC)
- Trial name
- NCT02312622
- Testing
- Pegylated Irinotecan
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Joel Neal